3 Reasons to Buy Novavax, Inc.

Novavax's recent decline could be a compelling buying opportunity.

Mar 28, 2014 at 6:30PM

The health care sector has fallen hard over the past month, and small caps in particular have led the sector lower. Because of the indiscriminate nature of this drop, I believe this rapid downturn could be creating some buying opportunities for investors with a long-term outlook. For example, the recombinant nanoparticle vaccine maker Novavax (NASDAQ:NVAX) is now down over 30% this month, yet the company offers a couple of compelling reasons to be optimistic about its future. With this idea in mind, here are my top three reasons why Novavax could be a bargain at current levels.

Reason No. 1
Novavax offers investors a strong clinical pipeline with multiple vaccines that have blockbuster potential. Chief among these candidates is Novavax's experimental vaccine for respiratory syncytial virus. The World Health Organization estimates that there are around 64 million new cases of RSV each year, and there is no prophylactic vaccine available for the majority of patient types. Specifically, AstraZeneca's (NYSE:AZN) palivizumab (brand name Synagis) is available for preterm babies born earlier than 35 weeks, but there are no treatment options for infants or elderly patients who are highly susceptible to RSV infections. Novavax's mid-stage experimental RSV vaccine would target three distinct patient populations: infants, young children, and the elderly. Thus far, the company has successfully completed a mid-stage trial for women of child-bearing age, and plans on initiating further mid-stage trials for other target populations later this year.

Novavax also has a growing influenza vaccine clinical program indicated for both pandemic and seasonal influenza. It reported some notable successes at the mid-stage level for its influenza vaccines over the past two years, and more trials are planned to begin later this year. Although the exact pathway to licensure is uncertain, i.e., accelerated or normal, I believe it could have a commercially available influenza vaccine on the market by 2016.

In terms of the commercial opportunity for influenza, the global flu vaccine market is expected to rise to around $4 billion as early as next year. Moreover, three big pharmas dominate this market space, namely AstraZeneca, GlaxoSmithKline (NYSE:GSK), and Novartis AG (NYSE:NVS). What's key to understand is that both GlaxoSmithKline and Novartis have developed new flu vaccines within the past two years in order to meet the growing demand, yet there is still a chronic annual shortage, showing that there is room for another player in this market. 

Reason No. 2
One of the things I like most about Novavax is the fact that it has a stable revenue source via its contract with BARDA to develop the next generation of influenza vaccines. The initial three-year period of the award provided Novavax with $52 million in revenue that allowed the company to build and improve infrastructure without having to dilute shareholders. Last February, this award period was extended for an additional seven months. Not many developmental biotechs can offer investors stable revenue streams at this stage of their life cycle.

Reason No. 3
When considering speculative clinical-stage biotechs, one of the first things I look at is insider buying versus selling. In Novavax's case, the company's president, Stanley Erck, and vice president, "Buck" Phillips, have made a number of buys on the open market this year. Last week, this trend continued as they both purchased shares on the open market. As these top-level managers presumably know the most about their company, I view these insider buys as a positive.

Foolish wrap-up
Novavax shares more than doubled in the last year prior to this pullback. And despite this recent dip, they are still up 97% over the past 12 months, so they haven't exactly crashed. My view is that Novavax soared along with the rest of the sector and has simply fallen in conjunction with its peers. Going forward, however, I believe there will be fewer and fewer developmental biotechs that will outperform the broader market, and those that do will likely have success on the clinical front. Based on the clinical successes for Novavax's recombinant nanoparticle vaccine platform to date, this company looks like it could be one of those winners. You might want to dig deeper into this speculative biotech, especially after its relatively large pullback in the past month.

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

    

George Budwell has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers